Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk

MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. 

Click here to learn how to join the action: https://www.ademilaw.com/case/dicerna-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Dicerna's financial outlook and prospects are excellent and yet Dicerna shareholders will receive only $38.25 per share in cash, which represents a total equity value of $3.3 billion. The merger agreement unreasonably limits competing bids for Dicerna by prohibiting solicitation of further bids, and imposing a significant penalty if Dicerna accepts a superior bid. Dicerna insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Dicerna's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Dicerna.

If you own Dicerna common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/dicerna-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP